<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02445508</url>
  </required_header>
  <id_info>
    <org_study_id>NCT02445508</org_study_id>
    <nct_id>NCT02445508</nct_id>
  </id_info>
  <brief_title>Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion</brief_title>
  <official_title>Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Accumulating evidence suggests that bile acids in our intestines may constitute essential
      components in the complex mechanisms regulating gut hormone secretion and glucose
      homeostasis. Thus, it is likely that modification of the enterohepatic circulation of bile
      acids can lead to changes in gut hormone secretion and consequently affect glucose
      homeostasis.

      The current study is a human interventional randomized controlled cross-over study including
      four study days for each participant. As a tool to sequester bile acids we will use
      sevelamer, a phosphate binding resin used in the treatment of hyperphosphataemia in adult
      patients with chronic kidney disease. Surprisingly, sevelamer has been shown to improve
      glycaemic control in patients with chronic kidney disease and type 2 diabetes. Intravenous
      infusion of cholecystokinin will be used to elicit gallbladder contraction and emptying. The
      aim is to examine how (and if) bile acid sequestration can influence postprandial
      glucagon-like peptide-1 (GLP-1) secretion and glucose homeostasis in patients with type 2
      diabetes.

      The investigators hypothesize that higher luminal concentrations of bile acids in the distal
      gut will elicit changes in gut hormone secretion. The current study will help to clarify this
      hypothesis and improve our general understanding of the association between bile acid
      circulation and signalling, gut hormone secretion and glucose metabolism.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucagon-like peptide-1 (GLP-1): Incremental and total area under the Concentration-Time Curve</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 45, 60, 90, 120, 180, 240 min on study days 1-4</time_frame>
    <description>Incremental and total area under the Concentration-Time Curve (AUC 0-240 min)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responses of various other gut hormones: Incremental and total area under the Concentration-Time Curve</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 45, 60, 90, 120, 180, 240 min on study days 1-4</time_frame>
    <description>Incremental and total area under the Concentration-Time Curve (AUC 0-240 min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood analysis of paracetamol as an assessment of gastric emptying</measure>
    <time_frame>-30, -15, 0, 10, 20, 30, 45, 60, 90, 120, 180, 240 min on study days 1-4</time_frame>
    <description>Assessment of gastric emptying</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indirect calorimetry: Basal metabolic rate</measure>
    <time_frame>-30 min to 240 min</time_frame>
    <description>Basal metabolic rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gallbladder volume as assessed by Ultrasound measurements</measure>
    <time_frame>-30 min to 240 min</time_frame>
    <description>Gallbladder volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite as assessed by Visual analog scale score</measure>
    <time_frame>-30 min to 240 min</time_frame>
    <description>Appetite</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Placebo+Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral ingestion of sevelamer placebo powder combined with intravenous infusion of isotonic saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+Cholecystokinin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral ingestion of sevelamer placebo powder combined with intravenous infusion of cholecystokinin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevelamer+Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral ingestion of sevelamer powder combined with intravenous infusion of isotonic saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevelamer+Cholecystokinin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral ingestion of sevelamer powder combined with intravenous infusion of cholecystokinin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer</intervention_name>
    <arm_group_label>Sevelamer+Placebo</arm_group_label>
    <arm_group_label>Sevelamer+Cholecystokinin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecystokinin</intervention_name>
    <arm_group_label>Placebo+Cholecystokinin</arm_group_label>
    <arm_group_label>Sevelamer+Cholecystokinin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer placebo</intervention_name>
    <arm_group_label>Placebo+Placebo</arm_group_label>
    <arm_group_label>Placebo+Cholecystokinin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic saline</intervention_name>
    <arm_group_label>Placebo+Placebo</arm_group_label>
    <arm_group_label>Sevelamer+Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes for at least 3 months (diagnosed according to the criteria of the
             World Health Organization (WHO))

          -  Men and postmenopausal women

          -  Metformin applied as the only anti-diabetic drug

          -  Caucasian ethnicity

          -  Normal haemoglobin

          -  Age above 40 years and below 70 years

          -  BMI &gt;23 kg/m2 and &lt;35 kg/m2

          -  Informed and written consent

        Exclusion Criteria:

          -  Liver disease (alanine aminotransferase (ALAT) and/or serum aspartate aminotransferase
             (ASAT) &gt;2 times normal values) or history of hepatobiliary disorder

          -  Gastrointestinal disease, previous intestinal resection, cholecystectomy or any major
             intra-abdominal surgery

          -  Nephropathy (serum creatinine &gt;150 ÂµM and/or albuminuria)

          -  Hypo- and hyperthyroidism

          -  Hypo- and hypercalcaemia

          -  Hypo- and hyperphosphataemia

          -  Active or recent malignant disease

          -  Treatment with medicine that cannot be paused for 12 hours

          -  Treatment with oral anticoagulants

          -  Any treatment or condition requiring acute or sub-acute medical or surgical
             intervention

          -  Any condition considered incompatible with participation by the investigators
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Center for Diabetes Research</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2015</study_first_submitted>
  <study_first_submitted_qc>May 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2015</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Andreas BrÃ¸nden</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sevelamer</mesh_term>
    <mesh_term>Bile Acids and Salts</mesh_term>
    <mesh_term>Cholecystokinin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

